NO331277B1 - Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit - Google Patents
Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kitInfo
- Publication number
- NO331277B1 NO331277B1 NO20034452A NO20034452A NO331277B1 NO 331277 B1 NO331277 B1 NO 331277B1 NO 20034452 A NO20034452 A NO 20034452A NO 20034452 A NO20034452 A NO 20034452A NO 331277 B1 NO331277 B1 NO 331277B1
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- nucleic acid
- antibody
- methods
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title 3
- 102000004196 processed proteins & peptides Human genes 0.000 title 3
- 108090000765 processed proteins & peptides Proteins 0.000 title 3
- 102000039446 nucleic acids Human genes 0.000 title 2
- 108020004707 nucleic acids Proteins 0.000 title 2
- 150000007523 nucleic acids Chemical class 0.000 title 2
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 208000032430 Retinal dystrophy Diseases 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 208000032578 Inherited retinal disease Diseases 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 201000006321 fundus dystrophy Diseases 0.000 abstract 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 208000007698 Gyrate Atrophy Diseases 0.000 abstract 1
- 208000027073 Stargardt disease Diseases 0.000 abstract 1
- 208000014769 Usher Syndromes Diseases 0.000 abstract 1
- 238000013399 early diagnosis Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 abstract 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 abstract 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0104712A FR2823221B1 (fr) | 2001-04-06 | 2001-04-06 | Sequences associees a la degenerescence retinienne et applications |
| PCT/EP2002/003810 WO2002081513A2 (en) | 2001-04-06 | 2002-04-05 | Disease-associated protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20034452D0 NO20034452D0 (no) | 2003-10-03 |
| NO20034452L NO20034452L (no) | 2003-12-04 |
| NO331277B1 true NO331277B1 (no) | 2011-11-14 |
Family
ID=8862037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034452A NO331277B1 (no) | 2001-04-06 | 2003-10-03 | Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US7795387B2 (cs) |
| EP (1) | EP1379657B1 (cs) |
| JP (2) | JP4370428B2 (cs) |
| KR (1) | KR100913258B1 (cs) |
| CN (1) | CN1529753B (cs) |
| AU (1) | AU2002312794B8 (cs) |
| BR (1) | BRPI0208870B8 (cs) |
| CA (1) | CA2443345C (cs) |
| CZ (1) | CZ305800B6 (cs) |
| EC (1) | ECSP024345A (cs) |
| ES (1) | ES2597835T3 (cs) |
| FR (1) | FR2823221B1 (cs) |
| HU (1) | HU226307B1 (cs) |
| IL (3) | IL158013A0 (cs) |
| MX (1) | MXPA03009114A (cs) |
| NO (1) | NO331277B1 (cs) |
| NZ (1) | NZ528376A (cs) |
| PL (1) | PL213658B1 (cs) |
| RU (1) | RU2384586C2 (cs) |
| SK (1) | SK288465B6 (cs) |
| WO (1) | WO2002081513A2 (cs) |
| ZA (1) | ZA200307403B (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2823221B1 (fr) * | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| EP2281877A3 (en) | 2003-05-21 | 2011-06-01 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| FR2870241B1 (fr) * | 2004-05-13 | 2015-02-27 | Novartis Ag | Facteur de viabilite des cones derive des batonnets ou rdcvf et applications |
| EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
| US9567382B2 (en) * | 2008-04-15 | 2017-02-14 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (RdCVF) |
| US8779093B2 (en) | 2008-09-10 | 2014-07-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuronal viability factor and use thereof |
| EP2383286A1 (en) | 2010-04-30 | 2011-11-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of retinal degenerative diseases |
| WO2013063383A2 (en) * | 2011-10-27 | 2013-05-02 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
| US20150038557A1 (en) | 2012-02-24 | 2015-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treatment of retinal degenerative diseases |
| EP2909232B1 (en) | 2012-10-17 | 2020-03-11 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd) |
| PL3027646T3 (pl) | 2013-07-31 | 2019-03-29 | Novartis Ag | Nowe wektory selekcyjne i sposoby selekcji eukariotycznych komórek gospodarza |
| JP6684343B2 (ja) | 2015-05-21 | 2020-04-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子の相乗組み合わせ及びその使用 |
| US10857240B2 (en) | 2016-01-05 | 2020-12-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| KR20190058388A (ko) * | 2016-10-11 | 2019-05-29 | 웰스테이트 옵탈믹스 코퍼레이션 | 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질 |
| EP4074828A4 (en) * | 2019-12-09 | 2023-12-27 | Chigenovo Co., Ltd. | Uses of cyp4v2 and rdcvf in preparation of drugs |
| CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院（北京大学第三临床医学院） | 一种分离的核酸分子及其用途 |
| WO2023280926A1 (en) * | 2021-07-07 | 2023-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies |
| CN113774019B (zh) * | 2021-08-11 | 2024-02-13 | 东南大学 | 一种脐带血间充质干细胞无血清培养基、培养方法及其应用 |
| US20240342313A1 (en) | 2023-03-30 | 2024-10-17 | Pharma Cinq, Llc | Vector encoding rod-derived cone viability factor and human igk signal sequence |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4771036A (en) * | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| GB9701710D0 (en) * | 1997-01-28 | 1997-03-19 | Karobio Ab | Mammalian protein |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| FR2784030B1 (fr) | 1998-10-02 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine |
| FR2784898A1 (fr) | 1998-10-26 | 2000-04-28 | Univ Pasteur | Utilisation du gdnf pour le traitement de la degenerescence retinienne |
| EP1033405A3 (en) * | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US8779093B2 (en) | 2008-09-10 | 2014-07-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuronal viability factor and use thereof |
-
2001
- 2001-04-06 FR FR0104712A patent/FR2823221B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-05 WO PCT/EP2002/003810 patent/WO2002081513A2/en not_active Ceased
- 2002-04-05 HU HU0303730A patent/HU226307B1/hu unknown
- 2002-04-05 RU RU2003130638/13A patent/RU2384586C2/ru active
- 2002-04-05 NZ NZ528376A patent/NZ528376A/en not_active IP Right Cessation
- 2002-04-05 JP JP2002579898A patent/JP4370428B2/ja not_active Expired - Lifetime
- 2002-04-05 ES ES02737923.9T patent/ES2597835T3/es not_active Expired - Lifetime
- 2002-04-05 CZ CZ2003-2706A patent/CZ305800B6/cs not_active IP Right Cessation
- 2002-04-05 BR BRPI0208870A patent/BRPI0208870B8/pt not_active IP Right Cessation
- 2002-04-05 EP EP02737923.9A patent/EP1379657B1/en not_active Expired - Lifetime
- 2002-04-05 IL IL15801302A patent/IL158013A0/xx unknown
- 2002-04-05 US US10/473,008 patent/US7795387B2/en not_active Expired - Lifetime
- 2002-04-05 KR KR1020037012934A patent/KR100913258B1/ko not_active Expired - Lifetime
- 2002-04-05 SK SK1223-2003A patent/SK288465B6/sk unknown
- 2002-04-05 PL PL364681A patent/PL213658B1/pl unknown
- 2002-04-05 CA CA2443345A patent/CA2443345C/en not_active Expired - Lifetime
- 2002-04-05 AU AU2002312794A patent/AU2002312794B8/en not_active Expired
- 2002-04-05 CN CN028094700A patent/CN1529753B/zh not_active Expired - Lifetime
- 2002-04-05 MX MXPA03009114A patent/MXPA03009114A/es active IP Right Grant
- 2002-11-19 EC EC2002004345A patent/ECSP024345A/es unknown
-
2003
- 2003-09-18 IL IL158013A patent/IL158013A/en unknown
- 2003-09-23 ZA ZA200307403A patent/ZA200307403B/en unknown
- 2003-10-03 NO NO20034452A patent/NO331277B1/no not_active IP Right Cessation
-
2007
- 2007-04-25 US US11/739,739 patent/US8114849B2/en not_active Expired - Fee Related
- 2007-04-25 US US11/739,734 patent/US8071745B2/en not_active Expired - Fee Related
-
2009
- 2009-03-04 JP JP2009050689A patent/JP4571695B2/ja not_active Expired - Lifetime
- 2009-06-11 IL IL199316A patent/IL199316A/en active IP Right Grant
-
2012
- 2012-01-11 US US13/348,383 patent/US8394756B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/348,435 patent/US8518695B2/en not_active Expired - Fee Related
-
2013
- 2013-06-04 US US13/909,764 patent/US8957043B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331277B1 (no) | Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit | |
| NO20045021L (no) | Immunologiske metoder og preparater for behandling av Alzheimers sykdom | |
| AU2003270643A1 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
| HK1053985A1 (zh) | 人類多肽引起或導致殺死細胞，包括淋巴腫瘤細胞 | |
| WO2003025121A3 (en) | Igf-binding protein-derived peptide or small molecule | |
| WO2002050277A3 (en) | Protein and nucleic acids encoding same | |
| JP2006506942A5 (cs) | ||
| NO996514L (no) | Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom | |
| WO2006087550A3 (en) | Amyloid-binding peptides, analogues and uses thereof | |
| CY1111431T1 (el) | Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων | |
| WO2003028543A3 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
| WO2006052821A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases | |
| WO2004015060A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
| WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
| WO2002099116A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
| WO2003059248A3 (en) | Pigment epithelium derived factor from human plasma and methods of use thereof | |
| WO2005113586A3 (en) | Disease-associated proteins | |
| WO2004031222A3 (en) | Dna vaccine encoding at least two nonstructural early proteins of papillomavirus | |
| WO2004043397A3 (en) | Compositions and methods for the treatment of rheumatoid arthritis | |
| WO2004111086A3 (fr) | ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE | |
| BRPI0308978A8 (pt) | fragmentos de peptídeos sintéticos ativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |